{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-206325","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2021-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.412580+00:00","generated_at":"2026-06-30T07:52:09.351760+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CareDx appoints Dr. Hannah Valantine to board; co-inventor of AlloSure technology","bullets":["Dr. Hannah Valantine appointed as Class I director effective July 1, 2021.","She is Professor of Medicine at Stanford and former NIH Chief Scientific Officer for Workforce Diversity.","She co-invented the donor-derived cell-free DNA technology (AlloSure) for transplant rejection monitoring.","Initial equity grants: option and RSU each with $150,000 grant-date fair value; annual cash retainer $40,000.","She also serves on board of Pacific Biosciences of California (Nasdaq: PACB) since June 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-206325","json":"https://secwatch.observer/filing/0001193125-21-206325.json","markdown":"https://secwatch.observer/filing/0001193125-21-206325.md","text":"https://secwatch.observer/filing/0001193125-21-206325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/0001193125-21-206325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/d196856d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T07:52:09.351760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bf30f070f","claim":"Hannah A. Valantine was appointed as Class I Director at CareDx, Inc..","evidence_excerpt":"On June 30, 2021, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed Hannah A. Valantine, M.D. as a Class I director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/0001193125-21-206325-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}